Celgene Receives Positive CHMP Opinion to Extend REVLIMID for Continuous Use in Patients with Newly Diagnosed Multiple Myeloma and Ineligible for Transplant Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation , today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion for continuous oral treatment with REVLIMID in adult patients with previously untreated multiple myeloma who are not eligible for stem cell transplantation. The CHMP reviews applications for all 28 member states in the European Union , as well as Norway, Liechtenstein and Iceland.
http://ift.tt/1v0f4tx
http://ift.tt/1v0f4tx
No comments:
Post a Comment